Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Daré Bioscience Inc (DARE)
NASDAQ:DARE
Holding DARE?
Track your performance easily
Earnings Data
Report Date
Mar 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.53Last Year’s EPS
-$0.84Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2024
|% Change Since: -23.98%
|Next Earnings Date:Mar 27, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including substantial nondilutive funding, progress in product pipeline and clinical trials, and steady market progress for XACIATO. However, challenges remain with decreased R&D spending, operational hurdles for Sildefanil Cream, and overall financial losses.Company Guidance
During the Q3 2024 earnings call for Daré Bioscience, various guidance metrics were provided. The company has secured over $20 million in nondilutive funding within 30 days, including a $10 million award from ARPA-H for their DARE-HPV program and a $10.7 million grant from the Bill & Melinda Gates Foundation to expedite the Ovaprene pivotal study. The call highlighted Daré's broad portfolio, which includes eight successful clinical trials and 25 FDA interactions across six product candidates between 2023 and 2024. Financially, Daré reported a comprehensive loss of $4.7 million for Q3, with $11.2 million in cash and cash equivalents and an 8.7 million share count as of November 13, 2024. General and administrative expenses were $2 million, and R&D expenses were $2.7 million, both reflecting a decrease compared to the previous year. Additionally, an equity line with Lincoln Park could provide up to $15 million, further supporting Daré's financial strategy and pipeline advancements.Significant Nondilutive Funding Acquired
Daré Bioscience secured over $20 million in nondilutive funding in the last 30 days, including a $10 million award from ARPA-H and a $10.7 million grant from the Bill & Melinda Gates Foundation.
Broad Portfolio and Pipeline Progress
Daré has conducted 8 successful clinical trials and held 25 FDA interactions across 6 product candidates in 2023 and 2024, demonstrating a robust pipeline focused on women's health.
XACIATO Sales and Market Progress
Steady month-over-month increases in XACIATO prescriptions, with Organon's women's health sales team securing preferred drug list status for Texas Medicaid, providing access to an additional 4.1 million patients.
Ovaprene Phase III Study Advancement
Enrollment in the Ovaprene pivotal Phase III clinical study is ongoing, supported by a central advertising campaign, with additional clinical sites to be added to accelerate the study.
DARE-HPV Program Development
Received a $10 million award to advance DARE-HPV, an investigational treatment for HPV-related cervical diseases, with plans for a Phase II clinical study.
---
DARE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DARE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $3.56 | $3.21 | -9.83% |
| Aug 12, 2024 | $3.50 | $4.20 | +20.00% |
| May 14, 2024 | $5.36 | $5.36 | 0.00% |
| Mar 28, 2024 | $9.33 | $8.33 | -10.72% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Daré Bioscience Inc (DARE) report earnings?
Daré Bioscience Inc (DARE) is schdueled to report earning on Mar 27, 2025, TBA Not Confirmed.
What is Daré Bioscience Inc (DARE) earnings time?
Daré Bioscience Inc (DARE) earnings time is at Mar 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DARE EPS forecast?
DARE EPS forecast for the fiscal quarter 2024 (Q4) is -$0.53.
---